SAGE Therapeutics (SAGE) Tops Q1 EPS by 4c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($2.46), $0.04 better than the analyst estimate of ($2.50). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $2.41 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• MeiraGTx Holdings plc (MGTX) Tops Q2 EPS by 202c
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c